Craik Lab Overview

We explore the roles and mechanisms of enzymes, receptors, and membrane proteins in complex biological processes using a vast, cross-disciplinary toolset, and we develop technologies to facilitate these studies.

Check out some of our recent papers below:

• Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M^Pro inhibitors with potent in vivo efficacy (NEW)
• Recombinant Antibodies Inhibit Enzymatic Activity of the E3 Ubiquitin Ligase CHIP via Multiple Mechanisms (NEW)
• Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I complex Demonstrates the Antitumor Efficacy of Hapten-Based Strategies (NEW)

• Preparing for the next pandemic; New lead drugs to treat COVID-19 are beginning to emerge
• Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets
• High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
• A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
• Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine
• In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET